NEJM publishes daraxonrasib NSCLC data supporting Phase III program
Revolution Medicines (RVMD) published Phase I/II data in NEJM showing daraxonrasib's antitumor activity in RAS-mutant NSCLC. The study reported a 42% response rate and 8.3-month median progression-free survival. The company is advancing the drug in a Phase III trial. Daraxonrasib was recently approved for pancreatic cancer, marking the company's first commercial product.
How this was made
The 30-second read
Why it matters
The data provides a new growth catalyst ahead of the RASolve 301 Phase III trial.
Market read
Positive early‑stage data may lift RVMD stock and influence the broader oncology biotech sector.
What to watch
Potential safety concerns at higher doses and competition from Astellas' degraders could limit market share.
Background
Revolution Medicines recently received FDA approval for daraxonrasib in pancreatic cancer; this NEJM article adds NSCLC data.
Ticker impact
NEJM published Phase I/II data for daraxonrasib in RAS‑mutant NSCLC, first public disclosure of efficacy numbers.
Potential upside of 10‑15% if data spurs optimism ahead of Phase III start.
First peer‑reviewed data with 42% ORR and 89% DCR provides material new information for a biotech with a recently approved product.
Market effects
Strengthens the pan‑RAS inhibitor space and may pressure competitors targeting KRAS G12D/V/R.
US biotech sector could see modest rally as investors reassess RAS‑targeted pipelines.
Highlights broader interest in non‑G12C RAS mutations, relevant for global oncology investors.
Counterpoint
Data from a small, non‑randomized subgroup may overstate efficacy; Phase III could disappoint.
Key entities
- companyRevolution Medicines
Biotech developing pan‑RAS inhibitor daraxonrasib.
- companyAstellas
Competing developer of KRAS G12D degrader setidegrasib.
